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Calcemic and phosphaturic response to parathyroid hormone in normal
and chronically uremic dogs. It is well established that the calcemic
response to parathyroid hormone (PTH) is blunted in chronic uremia
and is corrected partially by l,25(OH)2D treatment. Recent evidence
suggests that PTH(l-34) and not PTH(l-84) may be the actual calcemic
fragment. Equivalent doses of both peptides were infused into five
normal dogs (GFR = 51 mI/mm) and eight dogs with a remnant kidney
and chronic renal insufficiency (GFR = 15 mI/mm). Both the calcemic
and phosphaturic responses were studied. Remnant dogs had a blunted
calcemic response to bPTH(1-84). The increase in fractional phosphate
excretion was similar. In contrast, the calcemic response to bPTH(l-34)
was equivalent in remnant and normal dogs. Treatment of uremic dogs
with 400 ng 1,25(OH)2D daily for 3 days restored the effect of bPTH(1-
84) on serum calcium and increased the control value for tubular
phosphate reabsorption from 28 3 ig/ml GFR to 37 4 tg/ml GFR (P
< 0.01). These results suggest that there is an impaired conversion of
PTH(l-84) to PTH(1-34) in chronic renal insufficiency and that 1,25
(OH)2D may be involved in metabolism of PTH(l-84). In addition, the
effect of PTH on fractional phosphate excretion is not magnified in
nonparathyroidectomized uremic dogs.
Reponses calcemiques et phosphaturiques a l'hormone parathyrol-
dienne chez des chiens normaux et urémiques chroniques. II est bien
connu que Ia réponse calcémique a l'hormone parathyroIdienne (PTH)
est diminuée lors de l'urémie chronique, et est partiellement corrigée
par un traitement avec de Ia I ,25(OI-l)2D. Des résultats récents sug-
gerent que la PTH (1-34) et non Ia PTH (1-84), pourrait Ctre le veritable
fragment hypercalcémiant. Des doses equivalentes des deux peptides
étaient perfuse chez cinq chiens normaux (GFR = 51 mI/mm) et chez
huit chiens ayant un rein restant rCduit, et une insuffisance rénale
chronique (GFR = IS mi/mm). Les rCponses calcemiques et phospha-
turiques étaient étudiées. Les chiens insuffisants rénaux avaient une
diminution de Ia réponse calcemique a Ia bPTH (1-84). L'augmentation
de I'excretion fractionnelle des phosphates était identique. Au con-
traire, Ia réponse calcemique ala bPTH (1-34) était equivalente chez les
chiens normaux et urCmiques. Le traitement des chiens urémiques avec
400 ng de 1 ,25(OH)2D chaque jour pendant 3 jours a restauré l'effet de La
bPTH (1-84) sur Ia calcémie et a augmenté Ia valeur contrôle de Ia
reabsorption tubulaire des phosphates de 28 3 ig/mI GFR a 37 4
g/ml GFR (P < 0,01). Ces résultats suggèrent que Ia conversion de Ia
PTH(1-84) en PTH (1-34) est altérCe dans l'insuffisance rénale chroni-
que et que Ia 1,25(OH)2D pourrait Ctre impliquee dans le mCtabolisme
de Ia PTH (1-84). En outre, l'effet de Ia PTH sur l'excrétion fraction-
nelle des phosphates n'est pas amplifle chez les chiens urémiques non
parathyroIdectomisés.
serves to excrete ingested phosphorus. Because a phosphate
load depresses the serum calcium concentration, this phospha-
tuna assists in returning serum calcium to previous levels [3].
Finally, PTH stimulates synthesis of l,25(OH)2D, thereby
increasing gastrointestinal calcium absorption [4]. These mech-
anisms maintain eucalcemia during broad variations of dietary
calcium intake.
The calcemic response to PTH is blunted markedly in uremic
man [5—7], and dog [8—111. This bone resistance to PTH may be
important in the genesis of secondary hyperparathyroidism.
Therapy with l,25(OH)2D improves, but does not correct, this
defect. Martinet al have demonstrated that bPTH(1-34) binds to
the isolated perfused canine tibia and causes an increase in
perfusate cAMP. bPTH(l-84) bound neither to bone nor gener-
ated cAMP in this model [12]. Tregear et al [13] have demon-
strated that bPTH(l-34) is more calcemic than bPTH(l-84) in
chicks. If the PTH(l-34) fragment is the actual calcemic pep-
tide, then impairment of peripheral metabolism of PTH(l-84) to
PTH(l-34) may contribute to the blunted calcemia seen in
chronic uremia. This hypothesis predicts that PTH(l-34) would
be more calcemic than PTH(l-84) in chronic uremia.
The purpose of this study was to compare the calcemic
responses of normal and uremic dogs to bPTH(1-84) and
bPTH(l-34) before and after l,25(OH)2D treatment. In addition,
the phosphaturic responses to PTH before and after
1,25(OH)2D were evaluated. The results demonstrate a blunted
calcemic but normal phosphaturic response to bPTH(l-84) in
chronic renal insufficiency. Treatment with l,25(OH)2D cor-
rected this defect. In addition, the calcemic response to
bPTH(1-34) in uremia was normal.
Methods
Experiments were performed in 13 adult female mongrel dogs
weighing 12 to 22 kg. The dogs were divided into two experi-
mental groups. One group included five animals with normal
renal function. The remaining eight animals were made uremic
by ligation of the majority of the branches of the left renal artery
followed by removal of the right kidney. The dogs were uremic
Parathyroid hormone (PTH) maintains serum calcium con-
centration within specific limits by at least four mechanisms:
First, PTH acutely shifts calcium from bone into extracellular
fluid [1]. Second, renal tubular calcium reabsorption is en-
hanced by PTH [2]. Third, the phosphaturic response to PTH
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GFR, mi/mm
SCa2, mEq/liter
S, mgldl
UV/GFR, p.g/mI
T/GFR, p.g/ml
FEB04 %
iPTH, pdEq/mi
Pre-D
52.6 ÷ 4.3
2.71 003
3.5 0.2
2.1
33.1 1.8
5.65 2.40
82.0 9.0
Post-D
49.4 + 3.5
2.80 0.01c
3.7 0.1
2.3 0.6
34.1 2.6
8.05 ÷ 1.23
Pre-D
14.9 2.8
2.60 0.04c
4.5 0.3
16.0 5.0
28.0 ÷ 3.0
29.86 ÷ 9J4c
389.0 50.0'
Post-D
14.6 1.3
2.69 0.03
5.0 0.4
15.0 30
37.0 + 4.0w
27.14 6.86
at least 6 months before the study. All dogs were maintained on
Purina® high protein diet, containing 1.6% calcium, 0,95%
phosphorus, 0.15% magnesium, and 196 units of vitamin D.
On the day of the experiment, the animals were studied in the
unanesthesized state, standing in a supporting sling after a 15-hr
fast. They had free access to water until the time of the
experiment arrived. A catheter was inserted into the bladder for
quantitative collection of urine, Venous catheters were placed
in the inferior vena cava through a hind limb vein for infusion
and blood sampling. After injection of a priming dose of
creatinine, a solution of 1.25% dextrose and 0.45% saline
containing creatinine was infused at a rate of 2 mI/mm.
After a 60-mm period of equilibration, three 20-mm control
periods were obtained. Thereafter, purified bovine parathyroid
hormone bPTH(1-84) (1,200 U/mg, Inolex Corp., Park Forest
South, Illinois) was infused at the rate of 4 U/kg/hr for 3 hr. The
PTH was dissolved in 54 ml of 0.45% saline and infused at 0.3
mI/mm. Starting immediately after the control periods and with
initiation of the PTH infusion, seven 1-hr experimental clear-
ance periods were obtained. At the end of each period, the
bladder was washed with 30 ml of sterile water to insure
complete urine collection. At the midpoint of each period, a
sample of blood was collected anaerobically. The dogs then
received 400 ng synthetic I ,25(OH)2D i.v. for 3 consecutive
days (kindly provided by Dr. M. Uskokovic, Hoffman-
LaRoche, Nutley, New Jersey). The PTH infusion protocol was
then repeated. The identical protocol was repeated 2 to 12
weeks later with bPTH(1-34) (Beckman Co., Palo Alto, Califor-
nia) at the same dosage, 4 U/kg/hr for 3 hr. The dogs were given
the same dose of 1,25(OH)2D for 3 days and the bPTH(1-34)
infusion was repeated. Both preparations of PTH are assigned
units according to activation of rat renal cortical adenylate
cyclase. The units per milligrams are assumed to be as labeled.
Three of the batches used in these experiments were tested for
activity in the dog renal cortical cyclase assay and found to be
equivalent by Dr. Kevin Martin, St. Louis, Missouri. in sepa-
rate experiments, three uremic dogs were infused with bPTH(1-
34) at a lower dose of 1.5 U/kg/hr before and after 1 ,25(OH)2D
therapy.
Inorganic phosphate and creatinine were measured in the
urine and blood by a modified autoanalyzer method (Technicon
Autoanalyzer II). Serum ionized calcium was determined with a
flow through electrode system (Orion Biomedical, Model SS-
20). Serum PTH was measured by a radioimmunoassay using
antisera CH-71 at a final dilution of 1:125000 [141. This antise-
rum cross reacts with intact hormone as well as NH2- and
COOH terminal fragments. All samples were measured in
duplicate at two different dilutions. PTH levels are recorded in
arbitrary units (lEq/ml) relating the potency of the test serum
to that of a standard hyperparathyroid serum obtained from a
dog with experimentally induced chronic renal failure.
Data are expressed as mean + SEM. Statistical analyses were
performed by the Prophet computer, utilizing one way analysis
of variance and Dunnet's multiple range test.
Results
The mean GFR in the five normal dogs was 52.6 4.3 ml/
mm. The eight dogs with remnant kidneys had a GFR of 14.9
2.8 mI/mm (Table 1). During infusion of bPTH(1-84) in normal
dogs, GFR did not change. In contrast, GFR increased slightly
with bPTH(l-84) in the uremic dogs by 3.7 0.7 mI/mm (P <
0.01 vs. control period). This increase persisted from the
second to the fifth hour of bPTH(l-84) and also occurred during
bPTH(l-34), 2.7 0.6 mI/mm (P < 0.01 vs. control period).
Therapy with l,25(OH)2D did not effect this observation.
Calcium studies. The mean serum ionized calcium concentra-
tion during control observations in the normal dogs was 2.71
0.03 mEq/liter, a value significantly higher than in the uremic
dogs, 2.6 0.04 mEq/liter (P < 0.05). Treatment with
l,25(OH)2D increased the ionized calcium by 0.09 0.02 mEq/
liter in the normal dogs and 0.09 0.03 mEq/liter in the uremic
dogs (both P < 0.05) (Table 1). While receiving bPTH(l-84), the
normal dogs increased their ionized calcium by a maximum of
0.31 0.04 mEq/liter (Fig. 1). The peak calcemia occurred
during the fourth or fifth hour after starting the PTH infusion.
After therapy with I ,25(OH)2D, the peak calcemia was 0.39
0.04 mEq/liter (0.1 <P < 0.05 vs. pre-D).
The peak calcemic response with hPTH(l-84) in the uremic
dogs was blunted, 0.20 0.02 mEq/liter (P < 0.05 vs. normal
dogs). Treatment with 1,25(OH)2D restored the maximal calce-
mic response to 0.35 0.03 mEq/liter, a value not different
from that observed in normal dogs (P < 0.01 vs. pre-D) (Fig. 1).
The maximal calcemic response to bPTH(1-34) was 0.30
0.05 mEq/liter in normal dogs, and 0.34 0.02 mEq/liter in
Table 1. Controla values in normal and uremic dogs before and after treatment with I ,25(OH)2D treatmenth
Normal Uremic
a Mean of six control values pre-infusion of bPTH(1-84) and bPTH(l-34).
h 400 ng/d iv. x 3 d.
P < 0.05 vs. normals.
P < 0.01 vs. normals.
P < 0.05 vs. pre-D.
P < 0.01 vs. pre-D.
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0.2 - 0 Normal
S Uremic
0.2 0 Normal
S Uremic
uremic dogs (Fig. 2). Therapy with 1 ,25(OH)2D had no effect on
these responses. Thus, in uremic dogs, a blunted calcemic
effect was seen only with bPTH(l-84), but not with bPTH(l-34).
Furthermore, 1,25(OH)2D treatment completely corrected the
abnormality.
A potential for l,25(OH)2D to enhance calcemia with
bPTH(l-34) could have been masked if the dose of the peptide
used was excessive. To evaluate this possibility, we infused
three of the uremic dogs with a lower dose of bPTH(l-34), 1.5
U/kg/hr. This resulted in a peak calcemic response of 0.08
0.05 mEq/liter. After three days of 1 ,25(OH),D treatment the
same dose of bPTH(1-34) elicited a calcemia of 0.18 0.08
mEq/liter.
Phosphorus studies. The mean serum phosphorus values
during the control period were 3.5 0.2 mg/dl in the normal
dogs and 4.5 0.3 mg/dl in the uremic dogs (P < 0.05) and did
not change significantly after 1 ,25(OH)2D treatment (Table 1).
During the bPTH(l-84) infusion in the normal dogs, serum
phosphorus decreased by a maximum of 0.54 0.15 mg/dl(P <
0.05 vs. control value; Table 2). In contrast, bPTH(l-.84)
increased serum phosphorus in the uremic dogs by 1.1 0.3
mg/dl, with (P < 0.01 vs. control). This increase was significant
during periods four to seven, in concert with the increased
calcemia. After treatment with l,25(OH)2D, bPTH(l-84) was no
longer phosphatemic. bPTH(1-34) increased the serum phos-
phorus by 0,7 0.2 in uremic dogs (P < 0.01 vs. control).
However, I ,25(OH)2D treatment had no effect on this response.
Control phosphorus excretion in the normal dogs averaged
2.1 0.9 ig/ml GFR (Table I), and increased with bPTH(l-84)
infusion by 9.7 1 .2 jig/mI GFR (P < 0.01 vs. control period;
Table 3). Phosphaturia in the uremic dogs averaged 15 6 jig/
ml GFR during the control period (0.1 <P < 0.05 vs. normal
dogs) and increased with bPTH(l-84) by 9.9 2.1 p.g/ml GFR,
an increase not different from the normal dogs. The peak
phosphaturia occurred during the third hour in both the normal
and uremic dogs. Therapy with I ,25(OH)2D in normal and
uremic dogs affected neither the degree of phosphaturia during
the control period, nor the response to bPTH(l-84). The phos-
phaturic response to bPTH(l-34) in uremic dogs before and
after l,25(OH)2D was 9.1 2 jig/mI GFR and 14.4 2.5 jig/mI
GFR, respectively (not shown in table). Thus, uremic dogs
manifest an absolute phosphaturic response to PTH equivalent
to normal dogs, and l,25(OH)2D treatment does not modify this
response.
Fractional phosphate excretion during the control period was
greater in the uremic dogs, 29.86 9.14%, then in the normal
dogs, 5.65 2.40, (P < 0.05; Fig. 3). However, the increase in
fractional phosphate excretion during the bPTH(l-84) infusions
was similar in both groups. Furthermore, vitamin D treatment
did not affect the response. Thus, on a per nephron basis, the
remnant kidney of nonparathyroidectomized dogs responds to
PTH as a normal kidney.
Discussion
A rise in the concentration of serum calcium after administra-
tion of PTH is primarily caused by the mobilization of bone
calcium into the extracellular fluid [11. Martin et al have
suggested that the calcemic action of PTH is dependent on the
bPTH(l-34) fragment [12]. The mechanism of the impaired
response to bPTH(l-84) in chronic uremia could involve either
impaired conversion of bPTH(1-84) to bPTH(l-34) or direct
bone resistance to bPTH(l-34). Studies with bPTH(l-34) have
not been described previously in uremic dogs. Our findings
indicate that the calcemic response to bPTH(l-34) in uremic
dogs is greater than that seen with bPTH(l-84). Hruska et al
have shown recently a marked reduction in hepatic clearance of
intact PTH in chronically uremic dogs [15]. Taken together,
these findings suggest that peripheral conversion of bPTH(l-84)
to bPTH(l-34) is impaired in chronic uremia. This defect may
contribute to the blunted calcemia.
A greater response to bPTH(l-34) then bPTH(l-84) could
reflect differences in dosage. However, equivalent dosages
were administered, as determined by renal cortical cylase
assay. Optimally, equimolar amounts of both peptides should
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Fig. 1. Maximal increase in serum ionized calcium concentration (mEq/
liter) during infusion of bPTH(l-84) in normal and chronically uremic
dogs before and after treaunent with 1,25(OH)2D.
I I
f
+
0T
bPTH(1-84) bPTH(1-34( bPTH(1-84) bPTH(1-34)
Fig. 2.Maximal increase in serum ionized calcium concentration (mEqi
liter) during infusion of bPTH(1-84) or bPTH(l-34) in normal and
chronically uremic dogs.
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Control 1 hr 2 hr 3 hr 4 hr 5 hr 6 hr 7 hr
3.5 0.2 3.5 0.2 3.2 0.2 3.0 + 0.2' 3.1 0.2 3.4 0.3 3.6 0.3 3.9 0.2
3.7 0.1 3.6 0.2 3.4 0.2" 3.0 0.2 3.0 Ole 3.0 Ole 3.4 0.1" 3.6 0.1
4.3 0.5 4.4 0.5 4.4 0.4 4.5 0.4 4.8 0.5'
5.1 0.3 4.9 0.4 4.8 0.4 4.5 0.3 4.6 '- 0.4
mgldl
4 p.1kg/hr X 3 hr
400 ng/day i.v. x 3 day
"P < 0.05 vs. control period.
P < 0.01 vs. control period.
Table 3. Phosphaturia in normal and uremic dogs with bPTH(1-84)" before and after treatment with l,25(OH)2D5
Control 1 hr 2 hr 3hr 4hr Shr 6hr 7hr
2.1 0,9 6.4 - 0.7" 10.7 ÷ 1.2" 11.2 + 0.8d 10.1 Il" 5.6 1.2 2.8 1.3 1.9 1.0
3.0 0.4 7.5 1.4 13.5 l.4d 11.9 l.3d 12.5 + 1.4" 7.4 1.4d 4.0 1.3 2.6 1.0
have been infused. However, a bPTH(l-84) preparation equiva-
lent in purity to the bPTH(1-34) product is not available.
Furthermore, if the molecular weight and activity of bPTH(1-
84) is 9500 and 842 U/mg and of bPTH(l-34) 4109 and 6000 UI
mg, 4 U of bPTH(1-84) and bPTFI(1-34) represent 0.5 nM and
0.16 nM, respectively. These calculations are based on the
assumption that the bPTH(l-84) is pure, and the calculations
therefore are subject to error. However, the molar dose of
bPTH(1-34) was less than bPTH(1-84). Nonetheless, the uremic
dogs demonstrated a greater calcemia with bPTH(l-34).
Resistance to the calcemic action of PTH was first noted by
Evanson in hypocalcemic patients with renal failure [161.
Massry et a! [5] extended these observations to a large number
of patients with varying degrees of renal insufficiency and
showed that the blunted calcemia occurs even in patients with
mild to moderate renal failure [5]. Further studies in acutely
uremic dogs indicated that l,25(OH)2D partially restored [9],
and in combination with 24,25(OH)2D completely restored the
calcemic response to parathyroid extract [10]. In contrast,
1 ,25(OH)2D had no effect on the blunted calcemia to parathy-
roid extract in acutely uremic rats [17]. We observed an
enhancement of calcemia with bPTH(l-84) after I ,25(OH)2D
treatment. The effect of 1 ,25(OH)2D could be due to either a
direct effect on bone or an accelerated metabolism of intact
PTH to its calcemic fragment PT-H(1-34). Our findings do not
distinguish between these two possibilities. The failure of
vitamin D treatment to enhance calcemia with high dose
bPTH(l-34) suggests that a maximal calcemic effect had been
reached.
The only previous study of calcemic resistance to PTH in
chronically uremic dogs, authored by Kaplan et al [8], con-
firmed both the blunted calcemia and partial correction with
l,25(OH)2D. Similar results have been observed in chronically
uremic rats [71. In contrast, our data show that the blunted
calcemic response in chronically uremic dogs is corrected
completely by 1 ,25(OH)2D treatment. Both studies utilized the
remnant kidney model of chronic renal failure and an identical
PTH infusion protocol. The source of the discrepancy is evident
upon examination of the calcemic response in the normal dogs
in each study. In Kaplan's study, the response was substantial-
ly greater than that seen in our normal dogs, while the respons-
es of the uremic dogs to bPTH(1-84), before and after
l,25(OH),D in both studies were similar. The only difference
between the groups of' normal animals in each study was the
dietary calcium intake. Our dogs ingested 4.8 g of calcium daily
as compared to 1.6 g in the previous study. It is interesting to
postulate that the higher calcium diet suppressed circulating
1,25(OH)2D levels in normal dogs, thereby decreasing the
calcemic response to PTH. It is unknown if variations in
circulating levels of 1 ,25(OH)2D modify the bone response to
PTH in normal dogs. However, it may be postulated that
animals ingesting a high calcium diet are less likely to require
bone calcium to maintain eucalcemia and would therefore
manifest less calcemia during PTH infusion, In contrast to
Normal
Pre-D
Post-D
Uremic
Pre-D
Post-D
Table 2. Phosphatemiaa in normal and urernic dogs with bPTH(l84)h before and after treatment with 1,25(OH)2DC
5.0 0.4 5.1 0.4e 5.3 0.4
4.7 0.4 5.0 0.4 4.9 0.5
Normal
Pre-D
Post-D
Uremic
Pre-D
Post-D
15 6 19 ÷ 6" 23 5d 26 5" 25 5'
14 + 4 19 3e 25 3" 27 2" 24 + 2"
4 p./kg/hr x 3 hr
400 ng/day i.v. x 3 day
P < 0.05 vs. control period.
d P < 0.01 vs. control period.
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fractional phosphate excretion in uremic and normal dogs in our
study indicates that intact uremic dogs do not respond to PTH
in an augmented fashion. It has been shown recently that
parathyroidectomy will unmask an exaggerated phosphaturic
response to PTH in rats with a remnant kidney [22]. Yanagawa,
Houston, and Fine [23] found a diminished response to exoge-
nous PTH in the isolated perfused proximal tubule of remnant
kidneys from hyperparathyroid rabbits but found an exaggerat-
ed response in tubules from euparathyroid uremic rabbits.
Furthermore, Carnes et al [24] have demonstrated that the renal
cortical adenylate cyclase response to vitamin D deficient rats
with secondary hyperparathyroidism is blunted. However,
parathyroidectomy restores this response to normal. The ab-
sence of an enhanced response to PTH in our study may be due
to occupation of receptor sites by the high endogenous circulat-
ing concentrations of PTH.
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FE04 33.42 4.11 36.77 4.07 24.99 4.0 32.19 5.46
mgPO4excreted 140+10 157+17 46+8** 63+14**
Fig. 3. Fractional excretion of phosphate (FE04) bfore (C) and during
bPTH(1-84) infusion in normal and uremic dogs. Each dog was infused
with bPTH(1-84) before and after 3 days of I ,25(OH)2D treatment. The
increase in FE04 was significant in all groups (P 0.01). FEB04 is the
maximal increase during PTH infusion. The asterisk represents P <
0.05 vs. normal dogs. Two asterisks represent P < 0.01 vs. normal
dogs.
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Massry et al [11], our normal dogs had an augmented calcemia
to bPTH(1-84) after l,25(OH)2D treatment. The source of the
discrepancy is not evident. However, Massry et al [11] studied
chronically thyroparathyroidectomized dogs given parathyroid
extract for 8 hr and maintained on an unspecified amount of
dietary calcium. Furthermore, the calcemic response in their
dogs was more than twice that observed in our dogs. This large
response may have masked an additive effect of l,25(OH)2D,
In any subject maintaining phosphorus balance, renal excre-
tion of phosphorus must equal the amount of phosphorus
absorbed from the gastrointestinal tract. When renal function is
reduced, continued maintainance of phosphorus balance re-
quires an increase in phosphate excretion per nephron. Uremic
dogs have an impaired ability to excrete a phosphorus load as
compared to normal dogs [3]. However, on a milligram per
milliliter GFR basis, uremic dogs demonstrate a greater excre-
tory capacity than normal dogs. This has been ascribed to an
enhanced response to endogenous PTH secreted after a phos-
phate load [18]. Alternatively, Swenson et al have shown that
uremic parathyroidectomized dogs given vitamin D can main-
tain phosphate homeostasis in an equivalent fashion to their
nonparathyroidectomized counterparts [19]. We have demon-
strated recently that uremic dogs treated with cimetidine main-
tain phosphate balance despite marked reductions in circulating
PTH [20, 21]. These results suggest that the enhanced phospha-
tuna is inherent in the remnant kidney and not dependent on a
magnified response to PTH. The finding of a similar increase in
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